Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
87221 trials found · Page 100 of 4362
-
Major trial shows lasting benefits for CF patients on new triple therapy
Disease control CompletedThe study evaluates the long-term safety and tolerability of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New combo shows promise in Tough-to-Treat stomach cancer
Disease control CompletedThe study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 28, 2026 21:34 UTC
-
New combo therapy shows promise in beating rare leukemia
Disease control OngoingIn this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim of this study is to compare the number of participants on each treatment that show no signs o…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Apr 24, 2026 16:18 UTC
-
Womb fluid therapy may save babies born without kidneys
Disease control Recruiting nowCongenital lower urinary tract obstruction (LUTO) is a heterogeneous group of congenital anomalies that lead bladder outlet obstruction. If a complete obstruction is present, the perinatal mortality is estimated to be as high as 90% because of severe pulmonary hypoplasia due to t…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
Immunotherapy duo shows promise in Tough-to-Treat bladder cancer
Disease control OngoingThis is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durva…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
New hope for lung cancer patients: immunotherapy trial aims to keep cancer at bay
Disease control OngoingThis is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Gene therapy and smart glasses aim to restore sight in blindness trial
Disease control OngoingThe objective of this study is to evaluate the safety and tolerability of escalating doses of a gene therapy called GS030-DP (injected study treatment) administered via a single intravitreal injection and repeated light stimulation using a medical device called GS030-MD (stimulat…
Phase: PHASE1, PHASE2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
New injection before surgery aims to stop Melanoma's return
Disease control Recruiting nowThe trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery …
Phase: PHASE3 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC
-
World-First larynx transplant trial aims to give voice back to three patients
Disease control Recruiting nowThe experience of face and hand composite tissue transplantations reported in the international community have mainly concerned trauma patients. Feasibility and individual benefit have been demonstrated for these indications, in properly selected patients. The first laryngeal tra…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
Could a poop transplant tame a troubled gut? major trial investigates
Disease control OngoingUlcerative colitis (UC) is a chronic relapsing inflammatory bowel disease. UC pathogenesis remains poorly understood but involves an inappropriate immune response toward an unbalanced gut microbiota (called dysbiosis) in predisposed hosts. The purpose of this study is to determi…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Scientists re-engineer Patients' own cells to attack incurable blood cancer
Disease control OngoingBackground: Multiple myeloma is a cancer of the blood plasma cells. It usually becomes resistant to standard treatments. Researchers have developed a procedure called gene therapy. It uses a person's own T cells, which are part of the immune system. The cells are changed in a la…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New hope for halting deadly lung crises
Disease control CompletedAcute exacerbations (AE) are a dreaded manifestation of idiopathic pulmonary fibrosis (IPF) that presents with rapidly worsening respiratory function over days to weeks. AE account for about 1/2 the deaths in IPF patients, and are refractory to all medical therapies attempted to …
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
One-Shot gene therapy tested for Long-Term safety in rare metabolic disorder
Disease control OngoingDetermine the long-term safety of DTX301 following a single intravenous (IV) dose in adults with late-onset ornithine transcarbamylase (OTC) deficiency.
Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Apr 13, 2026 20:23 UTC
-
Personalized immune cells target aggressive lymphoma in groundbreaking trial
Disease control TerminatedThe purpose of this study is to test the safety and efficacy of AUTO4 a chimeric antigen receptor (CAR) T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive selected T-Non-Hodgkin Lymphoma (NHL).
Phase: PHASE1, PHASE2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
First targeted attack on 'Undruggable' KRAS cancer mutation
Disease control OngoingEvaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New pill could stop lung Cancer's return after surgery
Disease control OngoingThis randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting. Participants in the experimental arm will receive alectinib at 600 mg orally twice da…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New hope for leukemia patients who relapse
Disease control CompletedThis is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subje…
Phase: PHASE3 • Sponsor: Arog Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New drug shows promise in leukemia battle
Disease control CompletedA phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. Abo…
Phase: PHASE3 • Sponsor: Arog Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC
-
Scientists reprogram Patients' own immune cells to hunt deadly brain cancer
Disease control OngoingThis phase I trial studies the side effects and best dose of memory-enriched T cells in treating patients with grade II-IV glioma that has come back (recurrent) or does not respond to treatment (refractory). Memory enriched T cells such as HER2(EQ)BBζ/CD19t+ T cells may enter and…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
New drug cocktail aims to shrink tough pancreatic tumors for surgery
Disease control OngoingThis research study is studying a combination of interventions as a possible treatment for pancreatic tumor. The interventions involved in this study are: * FOLFIRINOX which is made up of 4 different drugs: * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovori…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC